ArticleVaccines2022

Development of Cross-Reactive Antibodies for the Identification and Treatment of Synthetic Cannabinoid Receptor Agonist Toxicity.

Adam Worob et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.